A Morelli, M Singer, VM Ranieri, A D'Egidio… - Intensive care …, 2016 - Springer
Abstract Purpose Ventricular–arterial (V–A) decoupling decreases myocardial efficiency and is exacerbated by tachycardia that increases static arterial elastance (Ea). We thus …
R Poveda-Jaramillo, F Monaco, A Zangrillo… - … of Cardiothoracic and …, 2018 - Elsevier
β-Blockers are useful drugs in several clinical cardiologic scenarios. Their use in the perioperative period and in critically ill patients is increasing, but their effect on clinically …
T Ojima, M Nakamori, M Nakamura… - Journal of British …, 2017 - academic.oup.com
Background Atrial fibrillation is common after oesophageal surgery. The aim of this study was to evaluate whether landiolol hydrochloride was effective and safe in the prevention of …
Y Matsuishi, S Jesmin, S Kawano, S Hideaki… - Life sciences, 2016 - Elsevier
Among the dysfunctions and pathologies associated with sepsis, the underlying molecular mechanisms of sepsis-induced acute lung injury (ALI) are poorly understood. Endothelin …
Landiolol is an injectable ultrashort acting beta-blocker with high beta1 selectivity indicated for heart rate control of atrial fibrillation in the emergency and critical care setting …
M Unger, A Morelli, M Singer, P Radermacher… - Trials, 2018 - Springer
Background In patients with septic shock, the presence of an elevated heart rate (HR) after fluid resuscitation marks a subgroup of patients with a particularly poor prognosis. Several …
Landiolol is an ultra-short-acting, selective β1-adrenergic receptor blocker that was originally approved in Japan for the treatment of intraoperative tachyarrhythmias. It has …
Y Matsuishi, BJ Mathis, N Shimojo… - Vascular health and …, 2020 - Taylor & Francis
Background Landiolol hydrochloride, a highly cardio-selective beta-1 blocker with an ultra- short-acting half-life of 4 minutes, was originally approved by Japan for treatment of …
R Lall, D Mistry, E Skilton, N Boota, S Regan, J Bion… - BMJ open, 2021 - bmjopen.bmj.com
Introduction In 2013, a single-centre study reported the safe use of esmolol in patients with septic shock and tachycardia who required vasopressor therapy for more than 24 hours …